Epidemiology of Primary Brain and Central Nervous System Tumors in Korea by Lee, Chang-Hyun et al.
145
www.jkns.or.kr
Epidemiology of Primary Brain and 
Central Nervous System Tumors in Korea
Chang-Hyun Lee, M.D.,1 Kyu-Won Jung, M.S.,2 Heon Yoo, M.D., Ph.D.,3 Sohee Park, Ph.D.,2 Seung Hoon Lee, M.D., Ph.D.3 
Department of Neurosurgery,1 Seoul National University College of Medicine, Seoul, Korea
Korea Central Cancer Registry,2 Neuro-Oncology Clinic,3 National Cancer Center, Goyang, Korea
J  Korean  Neurosurg  Soc  48 : 145-152, 2010
Objective : The aim of this report is to provide accurate nationwide epidemiologic data on primary central nervous system (CNS) tumors in
Korea. Despite its importance, there are no accurate statistics on primary CNS tumors in Korea. We analyzed primary CNS tumors diagnosed in
2005 from the nationwide registry.
Methods : Data on primary CNS tumors diagnosed in 2005 were collected from the Korean Central Cancer Registry and the Korean Brain Tumor
Society. Crude and age-standardized rates were calculated in terms of gender, age, and histological type. Tumors of uncertain histology were
investigated individually at the corresponding hospitals and had their diagnoses confirmed.
Results : A total of 5,692 patients diagnosed with primary CNS tumors in 2005 were included in this study. CNS tumors occurred in females
more often than in males (female to male, 1.43 : 1). The most common tumor was meningioma (31.2%). Glioblastoma accounted for 30.7% of all
gliomas, and 19.3% of all malignant primary CNS tumors. In children under 19 years of age, both germ cell tumor and embryonal/primitive/
medulloblastoma were the most common tumors. 
Conclusion : This article is the first nationwide primary CNS tumor epidemiology report in Korea. Data from this study should provide valuable
information regarding the understanding of primary CNS tumors epidemiology in Korea. 
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INTRODUCTION
The conventional definition of central nervous system
(CNS) tumors is generally applied to tumors of the brain
and spine. However, the International Classification of
Diseases for Oncology, Third Edition (ICD-O-3) defined
tumors of the meninges, pituitary gland, pineal gland and
nerves as CNS tumors7). Brain tumors are defined as neo-
plasms of the brain parenchyme on the basis of ICD-O-3.
CNS tumors in this report encompass both brain and CNS
tumors.  
Primary CNS tumors are not common. However, the inci-
dence of CNS tumors has increased rapidly2,3,10). These
tumors may result in mental alteration and neurologic defi-
cits, and the social burden of CNS tumors is just as large as
that of other tumors. Therefore, an accurate understanding
of the epidemiology is needed to facilitate early detection/
treatment and prevention of CNS tumors. Many countries
have established CNS tumors registries, and their descriptive
epidemiologies have been reported2,3,6,8,9,15). However, there is
yet no accurate nationwide CNS tumor epidemiology in
Korea that makes policy-making for tumor screening and
early treatment difficult. There have been several trials inve-
stigating factors associated with CNS tumors in Korea.
However, these studies have been limited to a small number
of cases diagnosed in the hospital setting4,5,11,12,14). In 2002,
the Korean Neuropathology Study Group analyzed 3,221
cases of CNS tumors diagnosed in 13 centers between 1997
and 199814). Unfortunately, there was no nationwide data
available in Korea on CNS tumors at that time.
The Korean Ministry of Health and Welfare started a
nationwide, hospital-based cancer registry (Korean Central
Cancer Registry, KCCR) in 1980. In 2005, the first national
brain cancer statistics encompassing the years between 1999
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and 2001 were reported by the KCCR13). The KCCR data-
base is especially useful for showing trends of cancer occur-
rence in Korea. However, it only provides the incidence of
malignant CNS tumors, excluding benign and borderline
tumors. Since benign tumors can recur and may be inopera-
ble, non-malignant brain tumors may impose the same cost
on the society in terms of medical care and case fatality as
malignant brain tumors.
The KCCR and the Brain Tumors Registration Commi-
ttee (BTRC) of the Korean Brain Tumor Society together
estimated the incidence of CNS tumors. In 2004, the KCCR
revised its criteria for cancer registration in order to include
benign and borderline tumors of the CNS. Such criteria were
applied to newly diagnosed cases from 2005.
The objective of this report is to provide an accurate nation-
wide statistics of primary CNS tumors, inclusive of be-nign,
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Table 1. Incidences of primary CNS tumors according to histology and sex
Histology
Male Female Total
Total CR ASR Total CR ASR Total % Age* CR ASR
Tumors of neuroepithelial tissue 599 2.45 2.42 503 2.07 2.11 1,102 19.4 43.5 2.26 2.24
Pilocytic astrocytoma 27 0.11 0.17 32 0.13 0.2 59 1 11.1 0.12 0.18
Diffuse astrocytoma 2 0.01 0.01 6 0.02 0.02 8 0.1 32.3 0.02 0.02
Anaplastic astrocytoma 40 0.16 0.15 32 0.13 0.12 72 1.3 44.6 0.15 0.13
Unique astrocytoma variants 5 0.02 0.02 10 0.04 0.04 15 0.3 22.7 0.03 0.03
Astrocytoma, NOS 78 0.32 0.29 45 0.19 0.18 123 2.2 42.2 0.25 0.23
Glioblastoma 188 0.77 0.68 150 0.62 0.52 338 5.9 55.5 0.69 0.59
Oligodendroglioma 34 0.14 0.11 26 0.11 0.08 60 1.1 39.4 0.12 0.1
Anaplastic oligodendroglioma 20 0.08 0.07 18 0.07 0.06 38 0.7 42.5 0.08 0.06
Ependymoma/Anaplastic ependymoma 34 0.14 0.14 28 0.12 0.13 62 1.1 37.4 0.13 0.13
Ependymoma variants 3 0.01 0.01 1 0 0 4 0.1 44.9 0.01 0.01
Mixed glioma 9 0.04 0.03 9 0.04 0.03 18 0.3 44.2 0.04 0.03
Glioma malignant, NOS 52 0.21 0.21 59 0.24 0.24 111 2 51.6 0.23 0.22
Choroid plexus 8 0.03 0.04 7 0.03 0.03 15 0.3 40.9 0.03 0.04
Neuroepithelial 16 0.07 0.06 13 0.05 0.05 29 0.5 50.3 0.06 0.05
Non-malignant and malignant neuronal/ 41 0.17 0.17 30 0.12 0.15 71 1.3 24 0.15 0.16
glial, neuronal and mixed
Pineal parenchymal 2 0.01 0.01 4 0.02 0.01 6 0.1 36 0.01 0.01
Embryonal/Primitive/Medulloblastoma 40 0.16 0.24 33 0.14 0.25 73 1.3 7.5 0.15 0.25
Tumors of cranial and spinal nerves 272 1.11 0.97 362 1.49 1.25 634 11.1 50.2 1.3 1.11
Nerve sheath, non-malignant and malignant 271 1.11 0.97 361 1.49 1.25 632 11.1 50.3 1.3 1.11
Other tumors of cranial and spinal nerves 1 0 0 1 0 0 2 0 30.3 0 0
Tumors of meninges 453 1.86 1.65 1,322 5.45 4.27 1,775 31.2 57.6 3.65 3.02
Meningioma 406 1.66 1.48 1,279 5.27 4.11 1,685 29.6 58.1 3.46 2.85
Other mesenchymal, non-malignant and 19 0.08 0.08 17 0.07 0.06 36 0.6 39.6 0.07 0.07
malignant
Hemangioblastoma 28 0.11 0.1 26 0.11 0.1 54 1 45.7 0.11 0.1
Lymphomas and hemopoietic neoplasms 60 0.25 0.22 44 0.18 0.14 104 1.8 58.8 0.21 0.18
Lymphoma 60 0.25 0.22 44 0.18 0.14 104 1.8 58.8 0.21 0.18
Germ cell tumors and cysts 76 0.31 0.38 26 0.11 0.13 102 1.8 17.6 0.21 0.26
Germ cell tumors, cysts and heterotopias 76 0.31 0.38 26 0.11 0.13 102 1.8 17.6 0.21 0.26
Tumors of sellar region 403 1.65 1.47 498 2.05 1.74 901 15.8 45.1 1.85 1.58
Pituitary 340 1.39 1.2 448 1.85 1.51 788 13.8 46.3 1.62 1.33
Craniopharyngioma 63 0.26 0.28 50 0.21 0.23 113 2 35.2 0.23 0.25
Local extensions from regional tumors 3 0.01 0.02 13 0.05 0.05 16 0.3 36.8 0.03 0.03
Chordoma/Chondrosarcoma 3 0.01 0.02 13 0.05 0.05 16 0.3 36.8 0.03 0.03
Unclassified Tumors 471 1.93 1.86 587 2.42 1.79 1,058 18.6 64.4 2.17 1.81
Hemangioma 27 0.11 0.11 25 0.1 0.09 52 0.9 37.3 0.11 0.1
Neoplasm, unspecified 440 1.8 1.74 557 2.29 1.68 997 17.5 65.8 2.05 1.69
All others 4 0.02 0.02 5 0.02 0.02 9 0.2 50.6 0.02 0.02
Total 2,337 9.57 8.99 3,355 13.82 11.48 5,692 100 52.5 11.69 10.24
*Median age at diagnosis. ASR : age-standardized rate, CR : crude rate




A total of 5,473 cases were registered
by 265 hospitals. On reviewing medi-
cal records, 266 patients omitted previ-
ously were added. Basic information
such as the demographic characteristics
of patients, date of diagnosis, tools of
diagnosis, originating site and histolo-
gical type according to the ICD-O-3
were included7).
We conducted an ad hoc survey on
cases histologically unconfirmed by the
BTRC, and 2,812 cases of uncertain
histology were referred to each hospital
for revision and correction. There were 47 records deleted
from the final data analysis : 9 cases invalid site/ histology
combination and 38 cases confirmed to be non-brain tumors
after the survey. As a result, a total of 5,692 cases of newly
diagnosed CNS tumors were reported.
The histological verification rate was 58.7%. The radiol-
ogic diagnosis rate was 33.0%. The proportion of cases regis-
tered based on death certificates only (DCO%) was 6.6%.
Pituitary tumor, craniopharyngioma, meningioma, lympho-
ma, subependymal giant cell astrocytoma were included,
without histological confirmation.
Data processing
Primary CNS tumors with the following ICD-O-3 site
codes were included in the analysis : brain (C71.0-C71.9),
meninges (C70.0-C70.9), spinal cord, cranial nerves and
other parts of the CNS (C72.0-C72.9), and pituitary gland,
craniopharyngeal duct and pineal gland (C75.1-C75.3).
Their behavior was also classified by the ICD-O-3 code,
which are divided into 3 groups : benign, uncertain whether
benign or malignant, and malignant. Tumors with behavior
codes (fifth digit ICD-O morphology) 0, 1 and 3, respecti-
vely, were also included. Histology groupings were based on
the classification of the Central Brain Tumor Registry of the
United States (CBTRUS)3). These groupings were broadly
based on the World Health Organization (WHO) categories
for brain tumors. 
The population size used as a denominator to calculate
cancer incidence was the midyear population on 1 July. In
this report, we modified the registered population released
annually from the national statistics office to obtain the
midyear population1). Childhood tu-mors were defined as
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Fig. 1. Distribution of primary CNS tumors according to sex and ICD-O-3
tumor behavior.
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Table 2. The numbers of total and histologically confirmed cases listed in descending order of
frequency 
Histological group
Total count Histology (+)
n % n %
Meningioma 1739 30.6 1,026 31.1
Glioma 1008 17.7 865 26.2
Pituitary tumor 788 13.8 532 16.1
Nerve sheath tumor 634 11.1 408 12.3
Lymphoma 104 1.8 97 2.9
Germ cell tumors, cysts and heterotopias 102 1.8 95 2.9
Craniopharyngioma 113 2.0 85 2.6
Other mesenchymal, non-malignant and malignant 36 0.6 32 1.0
Embryonal/Primitive/Medulloblastoma 73 1.3 73 2.2
Hemangioma 52 0.9 30 0.9
Choroid plexus 15 0.3 14 0.4
Chordoma/Chondrosarcoma 16 0.3 12 0.4
Neoplasm, unspecified 997 17.5 25 0.8
All others 15 0.3 11 0.3
Total 5,692 100.0 3,305 100.0
Histology (+) : histologically confirmed cases
those diagnosed in patients less than 19
years of age.
Definition of rates
Incidence measures the occurrence of
newly diagnosed cases of disease. Cru-
de Rate is the rate of disease in an entire
population. Crude rate is frequently
adjusted for age to age-standardized
rate to a common standard population,
which allows for rate comparisons across
regions with different age structures.
RESULTS
Overall incidence
There were 5,692 newly diagnosed
CNS tumors from a population of 48.6
million in 2005 (Table 1). Among
them, 454 developed in children under
19 years of age. CNS tumors are the
seventeenth most common in adults
and the second most common in
children in Korea1). The overall crude
rate of CNS tumors in Korea was
11.69 per 100,000 person-years in
2005, and the rate in children was 3.63
per 100,000 person-years. Tumors
classified as benign, uncertain whether
benign or malignant, and malignant
tumors accounted for 58.7%, 10.6%
and 30.7% of all primary CNS tumors,
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Table 3. The numbers of total and histologically confirmed cases of gliomas
Glioma Total count Histology (+)
Histological group n % n %
Glioblastoma 338 33.5 316 36.5
Astrocytoma, NOS 123 12.2 110 12.7
Anaplastic astrocytoma 72 7.1 71 8.2
Pilocytic astrocytoma 59 5.9 58 6.7
Ependymoma/Anaplastic ependymoma 66 6.5 62 7.2
Oligodendroglioma 60 6.0 56 6.5
Anaplastic oligodendroglioma 38 3.8 38 4.4
Glioma malignant, NOS 111 11.0 23 2.7
Neuroepithelial 29 2.9 25 2.9
Mixed glioma 18 1.8 18 2.1
Unique astrocytoma variants 15 1.5 15 1.7
Protoplasmic & fibrillary astrocytoma 8 0.8 8 0.9
Non-malignant and malignant neuronal/ 71 7.0 65 7.5
glial, neuronal and mixed
Total 1,008 100.0 865 100.0
Histology (+), histologically confirmed cases
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Germ cell tumor, 1.8%
Glioblastoma, 5.9%
Astrocytoma, NOS, 2.2%




All other glioma, 4.6%
Anaplastic astrocytoma, 1.3%
Local extensions from 
regional tumors, 0.3%
respectively (Fig. 1). Histological con-
firmation was achieved in 58.1% (3,305
cases). The number of total and histol-
ogically confirmed cases is listed in des-
cending order of frequency in Table 2. 
Incidence according to tumor 
biological behavior 
The overall incidence according to
biological behavior is shown in Fig. 1.
The incidence in males was 41.1%, and
the incidence in females was 58.9%.
The incidence of benign CNS tumors
was twice that of malignant tumors in
adults. Benign tumors developed nearly
twice more frequently in females than
in males (M : F = 1120 : 2221). In con-
trast, the incidences of uncertain and
malignant tumors were noted to be
similar or more frequent in males. 
Distribution of tumors 
according to the originating site
The incidence according to the origi-
nating site is shown in Fig. 2. Brain
parenchyma (40.1%) was the most
common site of primary CNS tumors,
followed by the meninges (31.2%),
sellar region (17.6%) and nerves
(11.1%). Parenchymal brain tumors
were most frequently located within
the frontal lobe, followed by the cere-
bellum, temporal lobe and parietal lobe.
Meningiomas were most frequently
located within the cerebral meninges
(82.5%), followed by meninges NOS
and spinal meninges. Tumors of the
meninges developed 3 times more fre-
quently in females (Fig. 2). The other
sites showed no significant differences
in incidence according to sex. The ma-
jority of sellar tumors originated in the
pituitary gland (85%). Tumors of the
cranial nerves most commonly originated from the eighth
cranial nerve.
The overall incidence of primary CNS tumors increased
with age until the seventh decade. The incidence of each site-
specific tumor according to age is shown in Fig. 3. Tumors of
the brain parenchyme were observed in all age groups and
reached a peak in the seventh decade. Tumors of the men-
inges seldom occurred in childhood, the incidence of which
increased in the third decade and peaked in the seventh
decade. Tumors of the nerves occurred in a few children and
peaked in the sixth decade. Sellar tumors in children were
also reported occasionally. Their incidence increased rapidly
in late adolescents and reached a peak in the fifth decade,
which decreased thereafter.
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Table 4. Detailed tumor behavior in histologically unclassified tumors and all others
Type ICD-O-3 code Behavior Count
Neoplasm,  8000/0 Neopasm, benign 192
unspecified  8000/1 Neopasm, uncertain whether benign or malignant 108
(997 cases) 8000/3 Neoplasm, malignant 696
8010/3 Carcinoma, NOS 1
All others 8720/3 Malignant melanoma, NOS 3
(9 cases) 9173/0 Cystic lymphangioma 5
9751/1 Langerhans cell histiocytosis, NOS 1
ICD-O-3 : the International Classification of Diseases for Oncology, Third Edition
Fig. 5. Incidence according to sex and histology.
Total
Meningioma
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Fig. 6. Distribution of primary CNS tumors according to the originating site and histology in children.
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All other glioma, 10.3%
Astrocytoma, NOS, 4.5%
Anaplastic astrocytoma, 1.7%
Incidence according to specific histology
Distribution of the tumors according to histology is shown
in Fig. 4. Histologically, tumors of the meninges were the
most common (31.2%), and neuroepithelial tumors were
the second most common (19.4%). Neuroepithelial tumors
were composed of glioma, ganglioneuroma, neurocytoma,
primitive neuroectodermal tumor, pineal tumor and retino-
blastoma. Most of the neuroepithelial tumors were gliomas
(91.5%), which accounted for 17.7% of all primary CNS
tumors and were the second most common histology. Glio-
blastoma accounted for 5.9% of all tumors and 33.5% of all
gliomas. Among histologically confirmed cases, glioblastoma
accounted for 36.5% of all gliomas (Table 3). Sellar tumors
and nerve sheath tumors, which were confirmed by patholo-
gists, accounted for 16.1% and 12.3%, respectively, of all
tumors.
The overall incidence according to gender and histology
are presented in Fig. 5. The incidence of meningioma was
almost 3 times higher in females than in males. Nerve sheath
tumor, pituitary tumor and pilocytic astrocytoma were also
more common in females than in males. On the other hand,
germ cell tumor, glioma (except pilocytic astrocytoma) and
lymphoma were more common in males than in females.
We classified tumors according to CBTRUS. Unclassified
tumors include unspecified neoplasms and all other tumors.
Unspecified neoplasms refer to cases registered based on
death certificates only. We did not have any specific data
other than neoplasm in those cases. The tumors which
classified into all others were tumors that did not meet
CBTRUS criteria. Unclassified tumors accounted for 17.5%
of all CNS tumors. The detail is described in Table 4.
Among the unclassified tumors, benign, borderline and
malignant tumors were found in 192, 108 and 697 patients,
respectively. As registered according to the ICD-O-3 code,
715 patients were diagnosed with brain parenchymal tu-
mors (C71). Tumors of the brain parenchyme, nerve/spinal
cord/meninges, sella and pineal gland were found in 714,
102, 96 and 85 patients, respectively. The other tumors did
not meet CBTRUS criteria. Malignant melanoma, cystic
lymphangioma and Langerhans histiocytosis were found in
3, 5 and 1 patients, respectively.
Distribution of childhood primary CNS tumors 
according to histology
Distribution of tumors according to histology is shown in
Table 3 and Fig. 6. The most common histology in children
included glioma and germ cell tumor. Glioma accounted for
52.6% of all brain tumors in children. Medulloblastoma was
the most common tumor among neuroepithelial tumors in
children. Glioblastoma accounted for only 3% of all primary
brain tumors in children, in contrast to adults.
Incidence in children according to age and 
histology
The age-standardized incidence in children according to
histology is shown in Table 5. Among the 0-4 age group, the
J Korean Neurosurg Soc 48 | August 2010
150
Table 5. Incidences of primary CNS tumors according to histology and sex in children (ages 0-19 years), 2005, Korea
Histology
Male Female Total
n CR ASR n CR ASR n CR ASR
Tumors of Neuroepithelial tissue 122 1.86 1.89 110 1.86 2.08 232 1.86 1.98
Pilocytic astrocytoma 22 0.33 0.37 21 0.35 0.41 43 0.34 0.39
Anaplastic astrocytoma 3 0.05 0.04 5 0.08 0.07 8 0.06 0.06
Astrocytoma, NOS 14 0.21 0.21 7 0.12 0.13 21 0.17 0.17
Glioblastoma 7 0.11 0.10 7 0.12 0.11 14 0.11 0.11
Ependymoma/Anaplastic ependymoma 8 0.12 0.13 6 0.10 0.14 14 0.11 0.14
Glioma malignant, NOS 7 0.11 0.10 14 0.24 0.25 21 0.17 0.17
Non-malignant and malignant neuronal/glial, 16 0.24 0.21 12 0.20 0.21 28 0.22 0.21
neuronal and mixed
Embryonal/Primitive/Medulloblastoma 33 0.50 0.54 30 0.51 0.61 63 0.50 0.57
Tumors of cranial and spinal Nerves 14 0.21 0.22 17 0.29 0.30 31 0.25 0.26
Tumors of meninges 11 0.17 0.16 14 0.24 0.20 25 0.20 0.18
Lymphomas and hemopoietic neoplasms 1 0.02 0.01 0 0.00 0.00 1 0.01 0.01
Germ cell tumors, and cysts 47 0.72 0.68 16 0.27 0.24 63 0.50 0.47
Tumors of sellar region 29 0.44 0.44 25 0.42 0.43 54 0.43 0.44
Pituitary 8 0.12 0.11 13 0.27 0.24 21 0.17 0.15
Craniopharyngioma 21 0.32 0.33 12 0.20 0.23 33 0.26 0.29
Local extensions from regional tumors 1 0.02 0.02 1 0.02 0.02 2 0.02 0.02
Unclassified tumors 19 0.29 0.31 27 0.46 0.42 46 0.37 0.36
Total 244 3.71 3.73 210 3.54 3.70 454 3.63 3.72
Abbreviation: CR, crude rate; ASR, age-standardized rate
incidence of primary brain tumors was the highest (3.14 per
100,000 person-years). The crude rate of the 5-9, 10-14 and
15-19 age groups accounted for 2.1, 2.05 and 2.74 per
100,000 person-years, respectively. In childhood, the inci-
dence of medulloblastoma, pilocytic astrocytoma, craniopha-
ryngioma and ependymoma decreased with age. In contrast,
the incidence of meningiomas, germ cell tumors and pitui-
tary adenomas increased with age.
Tumor incidence analysis in children showed different
disease patterns according to age. We divided the childhood
tumors into 2 groups according to age. Tumor distribution
of the 15-19 age group is different from that of the 0-14 age
group, but similar to the adult group. Embryonal/primitive/
medulloblastomas were the most common in children under
14 years of age, followed by germ cell tumor, pilocytic astro-
cytoma and craniopharyngioma. Germ cell tumor was re-
ported to be the most common in the ≥ 15 age group, follow-
ed by pituitary tumor, nerve sheath tumor and meningioma.
DISCUSSION
This is the first nationwide study on primary CNS tumors,
encompassing benign, borderline and malignant tumors in
Korea. Primary CNS tumors are not common. However, the
diag-nosis rate of tumors increases gradually, and they have a
great impact on patients as well as their families. Early detec-
tion and treatment are essential for improving the prognosis
of primary CNS tumors.
The overall crude rate for CNS tumors in Korea was 11.69
per 100,000 person-years in 2005, and the crude rate in child-
ren was 3.63 per 100,000 person-years. The age-standar-
dized rate of all primary CNS tumors in Korea, Japan and
the United States accounts for 10.2, 13 and 16.5 per 100,000
person-years, respectively3,6,10). Histologically confirmed diag-
noses accounted for 58% of all CNS tumors in Korea com-
pared to 73% in the Unites States and 86% in Japan. This
means that a considerable number of the final diagnoses of
our cases were made without histological confirmation. 
Incidences of most CNS tumors increased with age until
the seventh decade. Tumors of the meninges are very rare in
childhood. Tumors of the sella and nerves were occasionally
reported. They were related to hereditary tumors, such as
neurofibromatosis and multiple endocrine tumors. The inci-
dence patterns of embryonal/primitive/medulloblastoma,
pilocytic astrocytoma, ependymoma and germ cell tumors
reached a peak in early childhood then decreased with age.
Regarding incidence according to age, the incidence of pri-
mary CNS tumors was different between the <14 and 15-19
age groups. The incidence in the 15-19 age group was similar
to that in adults. 
Glioblastoma is well known to be the most aggressive and
to have the poorest prognosis. It is the most common tumor
originating from the neuroepithelium, regardless of sex in all
other countries. In 1996, glioblastoma was reported to ac-
count for 8.5% of all CNS tumors and 37.3% of all neuroe-
pithelial tumors in Japan. Between 2000 and 2004, glioblas-
toma was reported to account for 18.5% of all CNS tumors
and 51.2% of all neuroepithelial tumors in the Unites States.
In Korea, glioblastoma was shown to be 5.9% of all CNS
tumors and 30.4% of all neuroepithelial tumors. Glioblas-
toma can be diagnosed as a high-grade glioma or malignant
astrocytoma by magnetic resonance imaging. Therefore,
direct comparisons would be limited due to the differences in
data collection. Analyzing histologically confirmed cases,
glioblastoma accounted for 9.6% of all CNS tumors and
42% of the neuroepithelial tumors. The incidence of glioma
in Korea is not significantly different from that in Japan and
the Unites States.
Meningioma is the most common tumor of all primary
CNS tumors. Meningioma is often benign. It occurs in fe-
males predominantly. The female predominance of cases of
meningioma has also been reported in the United States and
Japan.
The second most common primary CNS tumor was pitui-
tary tumor, followed by cranial and spinal nerve tumors and
glioblastoma in Korea. The incidence of CNS tumors in
Japan showed the same order of frequency. In contrast, glio-
blastoma is the second most common CNS tumor in the
United States. Glioma is more common in Americans than
in Asians.
The limitations of this study are a relatively low rate of his-
tologically confirmed diagnoses and a short-term study period.
Long-term data and a precise reporting system are needed to
obtain more precise epidemiology. 
CONCLUSION
We reported the first nationwide statistics of all CNS tu-
mors in Korea. Epidemiologic data on all primary CNS tumors
for the purposes of accurately estimating their incidence are
mandatory for facilitating etiologic studies, establishing awa-
reness of the disease, and ultimately, for the control of tumors.
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